Drug intelligence / Profile preview

Zhu's Wenban Formula

Development stage: Unknown
Lead developer: Guangzhou University of Chinese Medicine
Administration: Oral

Overview

Zhu's Wenban Formula is a Traditional Chinese Medicine (TCM) compound granule formulation developed by the Guangzhou University of Chinese Medicine. It is a modified version of the classic Wendan Decoction, specifically designed for the treatment of carotid artery unstable plaques in patients at high risk for stroke. The formula aims to stabilize or reduce the size and number of plaques, likely through multi-target effects including anti-inflammatory and lipid-modulating activities. It has been evaluated in clinical trials to assess its efficacy and safety in early intervention for carotid atherosclerosis.

Other names: Wendan DecoctionZhu's Wendan Formula

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on Zhu's Wenban Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhu's Wenban Formula.

Explore the full profile